ArticleIsrael journal of health policy research2018

Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - a cost-utility analysis.

Gary M Ginsberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.